Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients

Abstract

CTLA4 blockers have limited activity in patients with chemorefractory lung cancer. Recent clinical data demonstrate that radiation therapy combined with CTLA4 blockers enables disease control in a sizeable fraction of these patients, correlating with increased circulating levels of type I interferon and dynamic changes in the peripheral T cell repertoire.

Keywords

• cgas
• ipilimumab
• non-small cell lung carcinoma
• sting
• trex1
• type i interferon